Literature DB >> 11473845

An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII.

H G Hendriks1, J M van der Maaten, J de Wolf, T W Waterbolk, M J Slooff, J van der Meer.   

Abstract

IMPLICATIONS: The successful treatment with recombinant factor VIIa of a patient experiencing intractable bleeding after cardiac surgery is described.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11473845     DOI： 10.1097/00000539-200108000-00009

Source DB:  PubMed          Journal:  Anesth Analg        ISSN： 0003-2999            Impact factor:   5.108


  14 in total

1.  Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography.

Authors:  G E Rivard; K E Brummel-Ziedins; K G Mann; L Fan; A Hofer; E Cohen
Journal:  J Thromb Haemost       Date:  2005-09       Impact factor: 5.824

Review 2.  Recombinant factor VIIa: a review on its clinical use.

Authors:  Massimo Franchini
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

Review 3.  The emerging role of recombinant-activated factor VII in neurocritical care.

Authors:  Matthew E Fewel; Paul Park
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

Review 4.  Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery.

Authors:  Robert J Porte; Frank W G Leebeek
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Decreasing the need for transfusion: infant cardiac surgery using hemodilution and recombinant factor VIIa.

Authors:  Peter D Winch; Aymen N Naguib; Jacob R Bradshaw; Mark Galantowicz; Joseph D Tobias
Journal:  Pediatr Cardiol       Date:  2012-07-04       Impact factor: 1.655

6.  Recombinant activated factor VII in paediatric cardiac surgery.

Authors:  Jonathan R Egan; Ahti Lammi; David N Schell; Jonathan Gillis; Graham R Nunn
Journal:  Intensive Care Med       Date:  2003-12-19       Impact factor: 17.440

7.  Postoperative pulmonary thromboembolism possibly associated with recombinant activated factor VII infusion for the treatment of uncontrolled hemorrhage during vertebral instrumentation.

Authors:  Zahid Hussain Khan; Alireza Ebrahim Soltani; Payman Rahmani
Journal:  J Anesth       Date:  2007-05-30       Impact factor: 2.078

Review 8.  Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma.

Authors:  Anthony E Pusateri; Myung S Park
Journal:  Crit Care       Date:  2005-10-07       Impact factor: 9.097

Review 9.  Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings.

Authors:  R Michael Grounds; Charles Bolan
Journal:  Crit Care       Date:  2005-10-07       Impact factor: 9.097

10.  Use of activated recombinant factor VII for severe coagulopathy post ventricular assist device or orthotopic heart transplant.

Authors:  Manish J Gandhi; Richard A Pierce; Lini Zhang; Marc R Moon; George J Despotis; Nader Moazami
Journal:  J Cardiothorac Surg       Date:  2007-07-06       Impact factor: 1.637
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.